Genetically Modified Cornea for Transplantation via MHC Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reducing immunogenicity in allogeneic corneal transplants, such as suppressing MHC class I or II expression, are not entirely effective in preventing immune responses and graft rejection in immunologically incompatible recipients, especially those with previous immune responses or neovascularization.
Innovation Solution
Genetically manipulating corneas ex vivo using nucleic acid constructs, specifically siRNA or shRNA expression cassettes targeting HLA-DR, DQ, DP, and β2-microglobulin genes, delivered via lentiviral vectors, to reduce MHC expression and immunogenicity, thereby minimizing immune responses and graft rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If MHC class I or II expression is suppressed in corneal transplants, then immunogenicity is reduced, but immune responses and graft rejection still occur in immunologically incompatible recipients
Solution Approach 1:
The patent segments the MHC complex into multiple target components: MHC class I (via β2-microglobulin suppression), MHC class II (via CIITA suppression), and HLA-DR/DQ/DP molecules. By using multiple independent shRNA expression cassettes targeting different segments of the MHC system, the patent achieves comprehensive immunogenicity reduction that cannot be accomplished by suppressing a single MHC component alone.
Solution Approach 2:
The patent creates a composite genetic modification system by combining multiple shRNA expression cassettes (targeting β2m, CIITA, HLA-DR, HLA-DQ, HLA-DP) within a single corneal graft. This composite approach integrates multiple immunosuppressive mechanisms into one therapeutic agent, achieving synergistic reduction of immunogenicity that addresses the limitations of single-target suppression.
2Ease of manufacture
If viral vectors are used to deliver shRNA, then genetic manipulation efficiency is improved, but risk of viral integration and off-target effects increases
Solution Approach 1:
The patent uses viral vectors as intermediary carriers to deliver shRNA expression cassettes into corneal cells. The viral vector serves as a mediator that facilitates efficient genetic material delivery while the shRNA payload provides the actual immunosuppressive function. This intermediary approach enables high-efficiency genetic manipulation while the modular design allows control over viral integration risks.
Solution Approach 2:
The patent employs different viral vector systems (lentiviral, adeno-associated viral, herpes simplex viral vectors) with varying integration properties. By selecting and optimizing viral vector parameters such as integration frequency, tropism, and expression duration, the patent achieves efficient genetic manipulation while managing the risk profile of viral delivery methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly reduces immunogenic reactions and graft rejection, as evidenced by minimal antibody production and T-cell infiltration, even in recipients with previous immune responses or inflammation, maintaining corneal structure and function post-transplantation.
Implementation Method 1
For introduction of the nucleic acid construct into the cornea, the nucleic acid construct can be contained in a viral vector, e.g. in a lentiviral vector, preferably packaged in lentiviral particles.
Implementation Method 2
The cornea is genetically manipulated to contain a nucleic acid construct containing an expression cassette encoding inhibitory RNA sequences, e.g. siRNA, preferably short-hairpin RNA (shRNA)
Data Source
Figure 1~2C
Figure 3
Figure 4A~4B
AI summary
The invention provides a cornea, which is ex vivo genetically manipulated in order not to elicit an immune response in an allogeneic recipient. The cornea is isolated, for use in transplantation and a method for production of a cornea, which is performed on an initial ex vivo, e.g. isolated cornea, for use in transplantation, e.g. for use in the treatment of cornea defects.